Our goal is to identify and develop therapeutic solutions for orphan diseases, which currently lack adequate pharmaceutical treatments.A rare disease is defined in Europe as one that affects fewer than one in 2,000 people.

(Source: [https://www.iss.it/malattie-rare])

Our current focus is on two serious rare conditions:  SBS (Short Bowel Syndrome) and CDD (Congenital Diarrheal Disorders), Microvillus Inclusion Disease (MVID) in particular. SBS is caused by a reduced intestinal surface area needed for the absorption of fluids and nutrients.

CDD refers to a group of rare inherited enteropathies characterized by severe chronic diarrhea in the first months of life. One example is MVID, a particularly severe form of CDD, often associated with intestinal failure and dependency on parenteral nutrition from birth.

Both SBS and CDD often cause chronic diarrhea, severe dehydration, metabolic acidosis or alkalosis, and malnutrition—symptoms that can arise quickly and become life-threatening.

It is estimated that SBS affects between 1 and 9 per 100,000 people. (Sources: orpha.net | sigenp.org)

There are currently no official sources available for the prevalence of MVID.